Free tool
FAERS Monitor: Zegerid Otc
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022281 or its brand name (Zegerid Otc, Omeprazole, Sodium Bicarbonate). Reports on generic versions are filed under their own applications.
Reports
339
Serious
294
87% of reports
Hospitalization
57
Death reported
29
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- chronic kidney disease224
- acute kidney injury120
- renal failure112
- renal injury82
- end stage renal disease65
- tubulointerstitial nephritis38
- gastrooesophageal reflux disease28
- nephrogenic anaemia25
- rebound acid hypersecretion25
- nephropathy15
- death13
- renal impairment12
- fatigue11
- hyperparathyroidism secondary11
- nausea11
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2010 | 2 |
| 2011 | 11 |
| 2012 | 6 |
| 2013 | 5 |
| 2014 | 6 |
| 2015 | 2 |
| 2016 | 9 |
| 2017 | 14 |
| 2018 | 46 |
| 2019 | 153 |
| 2020 | 28 |
| 2021 | 23 |
| 2022 | 9 |
| 2023 | 9 |
| 2024 | 7 |
| 2025 | 3 |
| 2026 | 6 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,820 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| rebound acid hypersecretionSignal | 25 | 517.0 | 353.9 | 12,265 |
| nephrogenic anaemiaSignal | 25 | 336.7 | 230.6 | 7,993 |
| hyperparathyroidism secondarySignal | 11 | 273.7 | 152.8 | 2,711 |
| end stage renal diseaseSignal | 65 | 221.9 | 178.3 | 14,036 |
| chronic kidney diseaseSignal | 224 | 183.4 | 169.9 | 40,491 |
| renal injurySignal | 82 | 171.7 | 142.2 | 13,727 |
| tubulointerstitial nephritisSignal | 38 | 126.0 | 93.4 | 4,585 |
| nephropathySignal | 15 | 99.8 | 60.8 | 1,369 |
| renal failureSignal | 112 | 52.4 | 45.0 | 5,623 |
| acute kidney injurySignal | 120 | 48.7 | 42.2 | 5,594 |
| gastrooesophageal reflux diseaseSignal | 28 | 21.6 | 15.1 | 531 |
| renal impairmentSignal | 12 | 8.9 | 5.1 | 76 |
| death | 13 | 0.9 | 0.5 | 0 |
| fatigue | 11 | 0.9 | 0.5 | 0 |
| nausea | 11 | 0.9 | 0.5 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.